key: cord-0964023-k8zlla0r
authors: Ahmed-Belkacem, Rostom; Sutto-Ortiz, Priscila; Guiraud, Mathis; Canard, Bruno; Vasseur, Jean-Jacques; Decroly, Etienne; Debart, Françoise
title: Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase
date: 2020-06-12
journal: Eur J Med Chem
DOI: 10.1016/j.ejmech.2020.112557
sha: 16d9e80a306594d9b3909f51ce4e7a742ee29d95
doc_id: 964023
cord_uid: k8zlla0r

The spreading of new viruses is known to provoke global human health threat. The current COVID-19 pandemic caused by the recently emerged coronavirus SARS-CoV-2 is one significant and unfortunate example of what the world will have to face in the future with emerging viruses in absence of appropriate treatment. The discovery of potent and specific antiviral inhibitors and/or vaccines to fight these massive outbreaks is an urgent research priority. Enzymes involved in the capping pathway of viruses and more specifically RNA N7- or 2’O-methyltransferases (MTases) are now admitted as potential targets for antiviral chemotherapy. We designed bisubstrate inhibitors by mimicking the transition state of the 2’-O-methylation of the cap RNA in order to block viral 2’-O MTases. This work resulted in the synthesis of 16 adenine dinucleosides with both adenosines connected by various nitrogen-containing linkers. Unexpectedly, all the bisubstrate compounds were barely active against 2’-O MTases of several flaviviruses or SARS-CoV but surprisingly, seven of them showed efficient and specific inhibition against SARS-CoV N7-MTase (nsp14) in the micromolar to submicromolar range. The most active nsp14 inhibitor identified is as potent as but particularly more specific than the broad-spectrum MTase inhibitor, sinefungin. Molecular docking suggests that the inhibitor binds to a pocket formed by the S-adenosyl methionine (SAM) and cap RNA binding sites, conserved among SARS-CoV nsp14. These dinucleoside SAM analogs will serve as starting points for the development of next inhibitors for SARS-CoV-2 nsp14 N7-MTase.

Emerging RNA viruses are serious threats to public health and have become a worldwide concern. The violent Ebola virus crisis in 2014 [1] (case fatality rate ≈ 50%) and the recurent outbreaks of Coronaviruses in 2003 (SARS-CoV, case fatality rate ≈ 10% [2] ), in 2012 (MERS-CoV, case fatality rate ≈ 36% [3] ) and in late december 2019 (SARS-CoV-2) [4] illustrate the critical impact of such viruses. The ongoing COVID-19 pandemic caused by the recently emerged new coronavirus, SARS-CoV-2 [4] , is a global health crisis touching every continent (187 countries) with severe economic impact. Most infected people display mild to moderate respiratory illness however patients having co-morbidty factors develop serious illness and pneumonia causing significant mortality [5, 6] . This disease endangers 7.7 billion people worldwide with in april 2020 more than 4 millions of confirmed cases of infected people and more than 250,000 confirmed deaths, and the number of COVID-19 cases will certainly progress in the next months with a possible rebond of the epidemic [7] . Despite this important public health threat, there are no yet approved chemotherapeutic agents or vaccines that can prevent or cure infections. Therefore, the urgent need of antivirals limiting the coronavirus propagation merits intensive efforts.

Most of single positive strand RNA viruses have evolved strategies in order to decorate the 5' end of their own genome by a cap structure mimiking the eukaryotic messenger RNA. This structure plays several key biological functions such as protection of RNA from 5'exoribonucleoases and initiation of the RNA translation into proteins. Moreover the cap is a marker of 'self' preventing detection by the cellular innate immunity mechanism. Thus viruses such as flaviviruses and coronaviruses code for RNA capping pathway mimiking that of eukaryotic cells. These viruses produce a subset of enzymatic activities including a RNA 5'triphosphatase, a guanilyltransferase (GTase) and two RNA cap methyltransferases (MTases) [8] . After the cap (GpppN) is set by the GTase, a first methylation occurs at N7 position of the guanine by a N7-MTase in the presence of methyl donor S-adenosyl methionine (SAM) yielding to a cap-0 ( 7m GpppN) followed by a further methylation that is achieved by a 2'-O-MTase at 2'position of the ribose of the first transcribed nucleotide in RNA yielding cap-1 ( 7m GpppN m ) (Scheme 1). The N7-and 2'-O-methylation of the viral RNA cap are key events for the viral infection as their inhibition might limit the synthesis of viral proteins and support virus elimination by stimulation of the immune response [9] . Therefore it is now admitted that the viral MTases are considered as attractive targets for the development of antiviral therapy [10, 11] . Few viral MTase inhibitors have been developed so far, however SAM-mimetics acting as competitors against the MTase co-substrate merit attention. Indeed SAM analogues such as sinefungin, 5'-methylthioadenosine (MTA) or S-adenosyl homocysteine (SAH) inhibit most of viral MTases with a potent efficiency but with a total lack of specificity [12] . This is certainly due to the high conservation of the shape and location of the SAM binding pocket in the human or different viral RNA MTases which share a common Rossman fold organization [13] . The rarity of specific inhibitors for viral MTases constitutes a stimulating challenge for new antiviral therapy but also for functional studies of these fascinating enzymes. With the aim of enhancing specificity of MTase inhibitors, we developed an approach of bisubstrate inhibitors that display a suitable linker between two adenosines that mimic the transition state of the methyl transfer reaction at 2'-O position of the RNA cap structure [12] .

One adenosine is supposed to target the SAM binding site and another adenosine would target the RNA binding site (Fig. 1 ). Recently, we described the synthesis of a first series of bisubstrate adenine dinucleosides with various sulfur-containing linkers [14] . Unexpectedly, such compounds tested at 50 µM or 200 µM concentration failed to inhibit several RNA 2'O-MTases of SARS-CoV, Zika, West Nile, Dengue and Pox viruses such as vaccinia virus. We thus explored their potential of inhibition toward N7-MTases of SARS-CoV and vaccinia virus and none of the S-linked dinucleosides was active against these N7-MTases. From these data, in the present work we replaced the sulfur atom (S) by a nitrogen atom (N) in the linker between both adenosines. This modification presents the advantage of increasing the chemical stability of the linker and offers a possible variability of compounds due to the N-substitution by any chain susceptible to interact with additional protein residues (Scheme 1). It is noteworthy that bisubstrate dinucleosides with N-containing linkers have already been reported in transition state analogues of DNA methylation [15] and of RNA methylation at N6 position of adenosine [16, 17] . However, till our work, none viral 2'O-MTase or N7-MTase have been targeted by bisubstrate adenine dinucleosides. This observation led us to explore the impact of N-linkers on the antiviral actvity of bisubstrate SAM analogs.

We thus synthesized a new series of transition state analogues of the RNA 2'-O-methylation reaction based on the coupling of a 2'-O-ethyl adenosine to a 5'-amino adenosine. We explored a variety of N-substituted linkers in adenine dinucleosides and their inhibition activity against several viral RNA 2'O-MTases was evaluated. Unexpectedly, none of the N-linked dinucleosides inhibited any 2'O-MTases of flaviviruses or SARS-CoV. However, when we extended the evaluation to SARS-CoV, vaccinia virus or human N7-MTases, interestingly some Nnitrobenzenesulfonamide-containing dinucleosides were found to specifically inhibit SARS-CoV N7-MTase nsp14 without inhibiting the cognate human N7-MTase or vaccinia N7-MTase. Such specific inhibition results from a high binding affinity of the most potent inhibitors to N7-MTase nsp14. In addition, computational docking analysis identified some residues of the binding site for the best inhibitor targeting nsp14. As SAM and RNA binding sites of N7-MTase nsp14 are almost completely conserved between SARS-CoV and 2 (95% sequence homology, Supporting Info Fig. S1 ) [18] , we can forecast that the candidate ligands that are efficient in inhibiting the SARS-CoV functions will be efficient in doing the same for SARS-CoV-2, this emphasizes the interest of the present work.

In order to mimic the transition state of the cap RNA 2'-O-methylation, the design of the SAM mimetics relies on the coupling of the adenosine moiety of the SAM cofactor to another adenosine modified at 2'-O-position with an ethyl group to form the link. Thus, we first synthesized the dinucleoside 1 with a 2'-O-ethyl amino link between both adenosines (Scheme 2). The major advantage of this N-containing linker is the possibility to functionalize the secondary amine with a large variety of groups which may lead to additional binding with specific sites of RNA 2'-O-MTases. According to the schematic representation of the transition state of the 2'-O-methylation (Scheme 1), an accurate mimic was represented by compound 2 with the α-amino acid chain of the SAM branched to the nitrogen atom [16] . We further modified this side chain under α-amino-ester form or α-amino-amide form to result in compounds 3 and 4, respectively. Then instead of polar modifications, we introduced hydrophobic substituents on the secondary amine in dinucleosides 5, 6 and 7. Finally we chose to obtain compound 9 with a nitrobenzenesulfonamide moiety as a structural particular element of the dinucleoside. Indeed, as a global observation in medicinal chemistry the N-arylsulfonamide motif is regularly found in antitumor agents as in some antiviral inhibitors [19, 20] . Further, we explored the combination of the nitro group with another substituent (MeO, CF 3 , Cl) at diverse positions in the phenyl ring resulting in the compounds 10-13 and we also removed the nitro group in 14 (Scheme 3). In addition, we chose to replace the sulfone by a methylene group in 15-16 (Scheme 4) to assess the sulfone contribution to the inhibitory activity obtained with dinucleosides containing the N-arylsulfonamide motif.

The retrosynthetic analysis of the dinucleoside 1 structure suggested the coupling reaction between the tosyl derivative 17 previously described by us (Scheme 2) [14] , and the readily accessible 5'-amino-2',3'-isopropylidene adenosine [21] . The direct N-alkylation at room temperature did not afford the secondary amine in satisfactory yields and when increasing the temperature to enhance the reactivity of the primary amine, we noticed degradation of 17. To circumvent the lack of reactivity of primary amines, a synthetic method using nitrobenzenesulfonamides (Ns-amides) as both a protecting and activating group has been developed by Fukuyama [22] . The main advantage of this nosyl strategy is that both alkylation and deprotection proceed under mild conditions. Recently, the 2-nitrobenzenesulfonamide has been used successfully to synthetize transition state analogues of DNA methylation based on the coupling of cytosine analogues to adenosine [15] . In the same way, we envisaged the coupling between 17 and the 5'-nosyl adenosine 18 to obtain the dinucleoside 1 (Scheme 2). The building block 18 was prepared in 74% yield by reacting 4-nitrobenzenesulfonyl chloride [22] that has a similar reactivity to 2-nitrobenzenesulfonyl chloride as used in ref [15] , with 5'-amino-2',3'isopropylidene adenosine prepared upon published procedures [23] . N-alkylation of Ns-amide 18 with 17 in the presence of K 2 CO 3 in DMF at room temperature did not afford the expected dinucleoside 19, even at high temperature. Nevertheless, according to the literature [24] , the addition of a catalytic amount of KI to the reaction mixture was beneficial to give 19 in 74% yield. Facile deprotection of 19 by treatment with a nucleophilic thiolate produced the desired secondary amine 20 in high yield. Removal of sugar protecting groups has been accomplished in acidic medium to give dinucleoside 1 in 76% yield. Likewise, the acidic treatment was applied to the intermediate Ns-amide 19 to afford the 4-nitrobenzenesulfonamide-containing dinucleoside 9

in 34% yield (Scheme 2). Compounds 2, 3 and 4 were obtained from key compound 20 via reductive amination of the aldehyde 21 that was prepared in three steps from L-aspartic acid following a published procedure [25] . Reductive amination was conducted in the presence of sodium triacetoxyborohydride and acetic acid [26] . The resulting fully protected dinucleoside 22 was with diverse Ns-amide moieties as analogues of the nosyl group (Scheme 3). The reaction of 5'amino-2',3'-isopropylidene adenosine [23] with four diversely substituted (OMe, CF 3 , Cl) and

commercially available nitrobenzenesulfonyl chloride reagents afforded the corresponding Nnosyl adenosines 26-29 with 40-72% yield [27] [28] [29] [30] . Their subsequent coupling with 17 in the presence of K 2 CO 3 and KI gave the corresponding dinucleosides 30-33 in moderate yields from 43 to 52%. A final TFA treatment provided the respective N-nosyl adenine dinucleosides 10-13

which were purified by reversed-phase chromatography (Yield 13-20%). 

Compounds 1-16 were tested for their ability to inhibit the methylation of the RNA cap structure. The inhibition induced by each compound (50 µM) was determined by a radioactive

MTase assay (filter binding assay) which consists in measuring the [ 3 H] radiolabeled methyl transferred from the methyl donor SAM onto RNA substrate (GpppAC 4 ) synthetized by using T7

primase [33] . Likewise, the compounds were also screened against human RNA N7-MTase (hRNMT) and

selected viral N7-MTases such as SARS-CoV nsp14 and Vaccinia D1-D12 complex (Table 1) .

Dinucleoside 2 bearing the amino acid chain of the SAM showed some significant inhibition of both viral N7-MTases with a better activity on Vaccinia D1-D12 than on SARS-CoV nsp14.

However, compound 2 also displayed a potent inhibition of hRNMT in the same range as the viral MTases displaying a lack of specificity against human and viral enzymes. The amino acid group of 2 seems essential for inhibition since compound 1 with a non-substituted NH linker weakly inhibited the three MTases. The replacement of the amino acid group with an α-aminoester at the extremity in compound 3 is detrimental for the inhibitory activity. Interestingly, the 

To confirm the observed inhibition of some adenine dinucleosides against SARS-CoV nsp14 N7-MTase, we further tested 10 compounds in a dose-response assay ( Table 2 , Supporting Information Fig. S2 ). The selection of these compounds was based on their percentage inhibition higher than 50% against SARS-CoV nsp14 (Table 1) also active against hRNMT [11] . Remarkably 13 bearing a chlorine atom in "para" position and a nitro group in "meta" position displayed the best inhibition which was 6.5 to 9.5 fold more potent than the derivatives 10 and 12, respectively that contain the nitro in "ortho" position and a lipophilic group CF 3 or MeO in "para" position. The comparison of IC 50 values of 14 and 13

indicates that the addition of a nitro group in the phenyl ring increased the inhibitory activity by 2.5 fold in 13. These results confirm that the chlorine atom in "para" position and the presence of a nitro group seem crucial for submicromolar SARS-CoV nsp14 inhibitory activity. values from the literature [11] . The MTase activity for IC 50 determinations was measured using a filter binding assay as described above. n.i: no inhibition detected at 50 µM; n.d: not determined due to inhibition lower than 50% at 50 µM.

SARS-CoV nsp14-inhibitor interactions were further investigated by monitoring the thermal stability of the protein using differential scanning fluorimetry (DSF) (Supporting Information, Fig. S3 ) [34] . The change in thermal stability of SARS-CoV nsp14 was monitored in response to binding of the natural cofactor substrate SAM, sinefungin and the 9 most active and specific compounds 6 and 9-16 with IC 50 < 100 µM. As expected, SARS-CoV nsp14 displayed an increased melting temperature (T m ) value with SAM (+6.5°C) and sinefungin (+4.4°C) whose structure only differs by a C-NH 2 in place of S + -CH 3 group in SAM (Fig. 2) . The binding experiments with the bisubstrate inhibitors showed that all dinucleosides stabilized the SARS-CoV nsp14 protein (T m > 40 °C) with a T m shift from +4.6 °C to +10.8 °C (Supporting Information, Table S1 ). Eight of the 9 examined compounds increased the stability of SARS-CoV nsp14 more efficiently than the well-known inhibitor sinefungin. More interestingly, T m values for SARS-CoV nsp14 were larger in the presence of five compounds 10 and 12-15 than with the natural enzyme substrate SAM, suggesting strong protein-inhibitor interactions.

Remarkably, the highest T m was observed with the most efficient inhibitor 13 (IC 50 0.6 + 0.1 µM) that stabilizes SARS-CoV nsp14 against thermal denaturation with a ∆T m +10. 8 

We 

General procedures. All dry solvents and reagents were purchased from commercial suppliers and were used without further purification. DIEA was distilled over calcium hydride. 

Following method C with 20 (117 mg, 0.14 mmol, 1.00 eq) and a 0-25% linear gradient of acetonitrile in TEAAc buffer 50 mM, pH 7 for purification, 1 (60 mg, 76%) was obtained as a white powder with 99% purity determined by HPLC analysis at 260 nm. 1 [M+H] + : 560.23242, found: 560.23188. 2-(N,N- ((((3aR,4R,6R,6aR )-6-(6-amino-9H-purin-9-yl)-2,2- ((((3aR,4R,6R,6aR )-6-(6-amino-9H-purin-9-yl)-2,2- N-(((3aR,4R,6R,6aR) 

oxy)ethyl)-4-chloro-3-nitrobenzenesulfonamide (33)

44 mmol, 1.00 eq), 33 (160 mg, 43%) was obtained as a pale white solid

CDCl 3 ) δ 8.29 (s, 1H), 8.28 (s, 1H), 8.116 (2s, 2H), 7.79 (s, 1H), 7.65 (dd, J = 8.4 Hz, J = 2.1 Hz, 1H)

m, 3H), 3.46 (q, J = 5.3 Hz, 2H), 1.56 (s, 3H), 1.35 (s, 3H), 0.92 (br. s, 9H), 0.90 (br. s, 9H

Using method C with 30 (167 mg, 0.16 mmol, 1.00 eq) and a 0-40% linear gradient of acetonitrile in TEAAc buffer 50 mM, pH 7 for purification, 10 (25 mg, 20%) was obtained as a white powder with 97% purity determined by HPLC analysis at 260 nm. 1 H-NMR (500 MHz, DMSO-d 6 )

Hz, 1H), 7.34 (br. s, 2H), 7.29 (br. s, 2H), 6.99 (dd, J = 9.0 Hz, J = 2.6 Hz, 1H), 5.95 (d, J = 5.2 Hz, 1H), 5.83 (d, J = 5.5 Hz, 1H), 5.65 (br. s, 1H), 5.49 (br. s, 1H), 5.38 (t, J = 5.7 Hz, 1H), 5.27 (br. s, 1H)

3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)ethyl

Hz, 1H), 7.34 (br. s, 2H), 7.29 (br. s, 2H), 6.99 (dd, J = 9.0 Hz, J = 2.6 Hz, 1H), 5.95 (d, J = 5.2 Hz, 1H), 5.83 (d, J = 5.5 Hz, 1H), 5.65 (br. s, 1H), 5.49 (br. s, 1H), 5.38 (t, J = 5.7 Hz, 1H), 5.27 (br. s, 1H)

12 (s, 1H), 8.11 (s, 1H), 7.88 (dd, J = 8.6 Hz, J = 1.8 Hz, 1H), 7.36 (br. s, 2H), 7.31 (br. s, 2H), 5.90 (d, J = 5.2 Hz, 1H), 5.82 (d, J = 5.4 Hz, 1H), 5.61 (d, J = 6.0 Hz, 1H), 5.43 (d, J = 5.1 Hz, 1H), 5.38 (dd, J = 6.6 Hz

HRMS (ESI+): m/z calcd for C 29 H

5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)ethyl)-4-chloro-3-nitrobenzenesulfonamide

DMSO-d 6 ) δ 8.42 (d, J = 2.2 Hz, 1H), 8.34 (s, 1H), 8.32 (s, 1H), 8.144 (s, 1H), 8.140 (s, 1H), 7.96 (dd, J = 8.5 Hz

Found 779.1730. N-(((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro

oxy)ethyl)-4-chlorobenzenesulfonamide (34)

41 mmol, 2.00 eq). 4-chlorobenzenesulfonyl chloride (65 mg, 0.31 mmol, 1.50 eq) was added at 0 °C and the reaction with brine (30 mL), dried over Na 2 SO 4 and concentrated under vacuum. The residue was purified by flash column chromatography (silica gel, linear gradient 0-4% MeOH in DCM) to give 34 (188 mg, 90%) as a white solid

CDCl 3 ) δ 8.32 (s, 1H), 8.29 (s, 1H)

After stirring for 20 min at 40 °C under argon, sodium triacetoxyborohydride (38 mg, 0.18 mmol, 1.50 eq) was added. After stirring at 40 °C for 16 h, the solution was diluted with DCM (30 mL) and washed with saturated aqueous NaHCO 3 . The aqueous layer was extracted with DCM (3 x 30 mL) and the combined organic extracts were washed with brine (60 mL), dried over Na 2 SO 4 and concentrated under vacuum. The residue was purified by flash column chromatography (silica gel, linear gradient 0-5% MeOH in DCM) to give 35 as a white solid (105 mg, 87%)

(m, 2H), 3.71 -3.66 (m, 1H), 3.65 -3.61 (m, 2H

)methyl)(4-chlorobenzyl)amino)ethoxy)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-9H-purin-6-amine (36). To a solution of 20 (210 mg, 0.25 mmol, 1.00 eq) in anhydrous DCE (7 mL) was added 4-chlorobenzaldehyde (43 mg, 0.38 mmol, 1.50 eq) in anhydrous DCE (7 mL) and acetic acid

°C for 16 h, the solution was diluted with DCM (50 mL) and washed with saturated aqueous NaHCO 3 . The aqueous layer was extracted with DCM (3 x 50 mL) and the combined organic extracts were washed with brine (70 mL), dried over Na 2 SO 4 and concentrated under vacuum. The residue was purified by flash column chromatography (silica gel

R f 0.71 (MeOH/CH 2 Cl 2 5:95). 1 H-NMR (600 MHz, CDCl 3 ) δ 8.30 (s, 1H)

m, 5H), 2.84 -2.66 (m, 4H), 1.58 (s, 3H), 1.36 (s, 3H), 0.92 (s, 9H), 0.88 (s, 9H

Using method C with 34 (150 mg, 0.15 mmol, 1.00 eq) and a 0-40% linear gradient of acetonitrile in TEAAc buffer 50 mM, pH 7 for purification, 14 (55 mg, 48%) was obtained as a white powder with 96% purity determined by HPLC analysis at 260 nm. 1 H-NMR

33 (s, 1H), 8.32 (s, 1H), 8.150 (s, 1H), 8.147 (s, 1H), 7.75 -7.68 (m, 2H), 7.53 -7.49 (m, 2H), 7.35 (br. s, 2H)

Using method C with 35 (140 mg, 0.14 mmol, 1.00 eq) and a 0-40% linear gradient of acetonitrile in TEAAc buffer 50 mM, pH 7 for purification, 15 (25 mg, 25%) was obtained as a white powder with 99% purity determined by HPLC analysis at 260 nm. 1 H-NMR (600 MHz

Hz, 1H), 7.32 (br. s, 2H), 7.24 (br. s, 2H), 5.99 (d, J = 5.9 Hz, 1H), 5.83 (d, J = 5.1 Hz, 1H), 5.51 -5.32 (m, 2H)

HRMS (ESI+): m/z calcd for C 29 H 34 N 12 O 9 Cl

mg, 37%) was obtained as a white powder with 98% purity determined by HPLC analysis at 260 nm. 1 H-NMR (600 MHz, DMSO-d 6 ) δ 8.36 (s, 1H), 8.25 (s, 1H), 8.13 (s, 1H)

Expression and purification of recombinant proteins SARS-CoV nsp14 and human RNA N7-methyltransferase (hRNMT) coding sequences were cloned in fusion with a N-terminus hexa-histidine tag in Gateway® plasmids. The proteins were expressed in E

Vaccinia virus capping enzyme (D1/D12 complex) and mRNA Cap 2´-O-methyltransferase (VP39) were purchased

The transfer of tritiated methyl from [ 3 H] SAM onto RNA substrate was monitored by filter SARS-CoV nsp14 (50 nM), vaccinia virus capping enzyme (D1-D12) (41 U), or human RNA N7 MTase (hRNMT) (50 nM). The enzymes were first mixed with compounds suspended in 100% DMSO (5% final DMSO) before the addition of RNA substrate and SAM and then diethylaminoethyl (DEAE) filtermat (Perkin Elmer) using a Filtermat Harvester (Packard Instruments). The RNA-retaining mats were washed twice with 10 mM ammonium formate pH 8.0, twice with water and once with ethanol. They were soaked with scintillation fluid

For IC 50 measurements, values were normalized and fitted with Prism (GraphPad software) using the following equation

)^Hillslope)). IC 50 is defined as the inhibitory compound concentration that causes 50% reduction in enzyme activity

Differential scanning fluorimetry (DSF)

The thermal stabilization of the native protein structure upon ligand binding was monitored by differential scanning fluorimetry, performed according to the method described previously [34] with some modifications. Reaction mixture (25 µL) consisted of 20 mM HEPES

The protein was first mixed with compound before the addition of the dye and incubated in 96-well white microplates

Molecular docking All calculations were performed using Autodock vina (The Scripps Research Institute

The solved X-ray crystal structure of SARS-CoV nsp14 (PDB 5C8T) was used as a static receptor for docking. Both the co-crystalized ligand SAM and ions were removed from the SARS-CoV nsp14 protein using VMD 1.9.3 software. The ligand structures were drawn and minimized using MarvinSketch (ChemAxon). Targeted protein and ligand structures with polar hydrogens were converted to the required PDBQT format using MGL Tools (version 1.5.6). The docking was performed with a search box located at x = -11.155, y = -40

Accession Codes PDB code for SARS-CoV nsp14 bound SAM is 5C8T. PDB code for SARS-CoV nsp14 is

Distinguishing epidemiological features of the 2013-2016 West Africa Ebola virus disease outbreak, Disaster health

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

SARS and MERS: Recent insights into emerging coronaviruses

A new coronavirus associated with human respiratory disease in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The Lancet

Coronavirus disease (COVID-19) outbreak situation

Biochemical principles and inhibitors to interfere with viral capping pathways

Mutagenesis of coronavirus nsp14 reveals its potential role in modulation of the innate immune response

Yeast-based assays for the high-throughput screening of inhibitors of coronavirus RNA cap guanine-N7-methyltransferase

Toward the identification of viral cap-methyltransferase inhibitors by fluorescence screening assay

SAM/SAH analogs as versatile tools for SAM-dependent methyltransferases

Structural and functional studies of Sadenosyl-L-methionine binding proteins: A ligand-centric approach

Synthesis of adenine dinucleosides 2′,5′-bridged by sulfur-containing linkers as bisubstrate SAM analogues for viral RNA 2′-O-methyltransferases

Hijacking DNA methyltransferase transition state analogues to produce chemical scaffolds for PRMT inhibitors

Synthesis of SAM-adenosine conjugates for the study of m6A-RNA methyltransferases

Bisubstrate analogues as structural tools to investigate m6A methyltransferase active sites

Structural genomics of SARS-CoV-2 indicates evolutionary conserved functional regions of viral proteins

Development of a convergent large-scale synthesis for venetoclax, a first-in-class BCL-2 selective inhibitor

Design and synthesis of heteroaromatic-based benzenesulfonamide derivatives as potent inhibitors of H5N1 influenza A virus

Selective inhibitors of histone methyltransferase DOT1L: Design, synthesis, and crystallographic studies

Ns strategies: A highly versatile synthetic method for amines

Synthesis and biochemical properties of chemically stable product analogs of the reaction catalyzed by S-adenosyl-L-methionine decarboxylase

Expedient catalytic construction of azabicyclo

Visualizing the reaction cycle in an iron(ii)-and 2-(oxo)-glutarate-dependent hydroxylase

A review on the use of sodium triacetoxyborohydride in the reductive amination of ketones and aldehydes

Development of hypoxia-sensitive Gd 3+ -based MRI contrast agents

Discovery of novel, drug-like ferroptosis inhibitors with in vivo efficacy

Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-α converting enzyme inhibitors

Catalytic asymmetric alkylation reactions for the construction of protected ethylene-amino and propylene-amino motifs attached to quaternary stereocentres

Synthesis and evaluation of 7-chloro-4-(piperazin-1-yl)quinoline-sulfonamide as hybrid antiprotozoal agents

Design, synthesis and biological evaluation of novel hamamelitannin analogues as potentiators for vancomycin in the treatment of biofilm related staphylococcus aureus infections

High-yield production of short GpppA-and 7me GpppA-capped RNAs and HPLC-monitoring of methyltransfer reactions at the guanine-N7 and adenosine-2'O positions

The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability

Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex

Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA

Halogen bonds in biological molecules

Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding

In vitro reconstitution of SARS-coronavirus mRNA cap methylation

Image for Table of Contents and Graphical Abstract: Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS

Highligths • Bisubstrates as mimics of RNA 2'-O-methylation transition state with SAM • 16 dinucleosides with two adenosines joined by various nitrogen-containing linkers • Bisubstrate compounds were barely active against viral 2'-O-methyltransferases • Discovery of a potent and specific inhibitor of SARS-CoV nsp14 N7-methyltransferase • Molecular docking and biophysical assays corroborated observed SAR Declaration of interests

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work

☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests

Rostom Ahmed-Belkacem acknowledges University of Montpellier for the financial support of his PhD work.

Supplementary data to this article can be found online at :

All authors have contributed to the manuscript and given approval to the final version of the manuscript.

The authors declare no competing financial interest.